Ajanta Pharma (NSE:AJANTPHARM) Beneish M-Score: -1.75 (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AJANTPHARM Ajanta Pharma Ltd NSE:AJANTPHARM
95 GF Score
Price ₹3,481.70
GF Value ₹3,348.50
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Ajanta Pharma Beneish M-Score?

Ajanta Pharma NSE:AJANTPHARM -0.66% 95 Beneish M-Score is -1.75 as of Sep. 03, 2026. GuruFocus rates NSE:AJANTPHARM with a GF Score™ of 95/100 and a GF Value™ of ₹3,348.50 (Fairly Valued). The stock has 6 warning signs investors should review. Among 918 Drug Manufacturers companies, Ajanta Pharma ranks worse than 85.19% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -1.75 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Ajanta Pharma's Beneish M-Score or its related term are showing as below:

NSE:AJANTPHARM' s Beneish M-Score Range Over the Past 10 Years
Min: -2.83   Med: -2.24   Max: -1.61
Current: -1.75

During the past 13 years, the highest Beneish M-Score of Ajanta Pharma was -1.61. The lowest was -2.83. And the median was -2.24.


Ajanta Pharma Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ajanta Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ajanta Pharma Beneish M-Score Chart

Ajanta Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.95 -2.83 -2.15 -2.61 -1.75

Ajanta Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.75 0.00

NSE:AJANTPHARM vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ajanta Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ajanta Pharma Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ajanta Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ajanta Pharma's Beneish M-Score falls into.


NSE:AJANTPHARM
95GF Score
Ajanta Pharma Ltd NSE:AJANTPHARM
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ajanta Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ajanta Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3209+0.528 * 0.9806+0.404 * 0.8971+0.892 * 1.1787+0.115 * 0.9337
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1114+4.679 * 0.085593-0.327 * 1.1502
=-1.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹18,770 Mil.
Revenue was ₹54,073 Mil.
Gross Profit was ₹41,596 Mil.
Total Current Assets was ₹37,354 Mil.
Total Assets was ₹61,548 Mil.
Property, Plant and Equipment(Net PPE) was ₹21,205 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,731 Mil.
Selling, General, & Admin. Expense(SGA) was ₹6,015 Mil.
Total Current Liabilities was ₹14,158 Mil.
Long-Term Debt & Capital Lease Obligation was ₹394 Mil.
Net Income was ₹10,560 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹5,292 Mil.
Total Receivables was ₹12,055 Mil.
Revenue was ₹45,875 Mil.
Gross Profit was ₹34,604 Mil.
Total Current Assets was ₹28,430 Mil.
Total Assets was ₹50,150 Mil.
Property, Plant and Equipment(Net PPE) was ₹19,005 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,441 Mil.
Selling, General, & Admin. Expense(SGA) was ₹4,591 Mil.
Total Current Liabilities was ₹9,961 Mil.
Long-Term Debt & Capital Lease Obligation was ₹347 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18769.7 / 54072.6) / (12055.3 / 45875.1)
=0.34712 / 0.262785
=1.3209

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(34603.6 / 45875.1) / (41595.6 / 54072.6)
=0.7543 / 0.769255
=0.9806

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (37354.3 + 21205.1) / 61548.4) / (1 - (28430.3 + 19004.5) / 50149.5)
=0.048563 / 0.054132
=0.8971

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=54072.6 / 45875.1
=1.1787

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1441.1 / (1441.1 + 19004.5)) / (1731.4 / (1731.4 + 21205.1))
=0.070485 / 0.075487
=0.9337

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6014.6 / 54072.6) / (4591.2 / 45875.1)
=0.111232 / 0.10008
=1.1114

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((394.2 + 14157.5) / 61548.4) / ((347.2 + 9961) / 50149.5)
=0.236427 / 0.205549
=1.1502

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(10560 - 0 - 5291.9) / 61548.4
=0.085593

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ajanta Pharma has a M-score of -1.75 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -1.75 mean?
Ajanta Pharma (NSE:AJANTPHARM) has a Beneish M-Score of -1.75 as of Sep. 03, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ajanta Pharma and its competitors. According to the industry distribution chart, Ajanta Pharma ranks #782 out of 918 companies in the Drug Manufacturers industry, placing it in the top 85.2%.
Is Ajanta Pharma's Beneish M-Score too high?
Ajanta Pharma's current Beneish M-Score is -1.75. Based on the distribution chart, Ajanta Pharma ranks #782 out of 918 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ajanta Pharma has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ajanta Pharma's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ajanta Pharma ranks #782 out of 918 companies for Beneish M-Score. This places Ajanta Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ajanta Pharma and its competitors. Ajanta Pharma's current Beneish M-Score is -1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ajanta Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ajanta Pharma (NSE:AJANTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹3,348.50, compared to a current price of ₹3,481.70 — trading 4% above its estimated fair value. The current Beneish M-Score is -1.75. Ajanta Pharma's overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ajanta Pharma (NSE:AJANTPHARM), the current Beneish M-Score is -1.75 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ajanta Pharma (NSE:AJANTPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Ajanta Pharma stock appears to be overvalued. The current stock price of ₹3,481.70 is trading 4% above its estimated GF Value™ of ₹3,348.50. GuruFocus considers Ajanta Pharma to be Fairly Valued.

Key valuation signals for NSE:AJANTPHARM:

  • Beneish M-Score: -1.75
  • GF Value™: ₹3,348.50 vs. price of ₹3,481.70 (4% above fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the NSE:AJANTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ajanta Pharma Business Description

Other Exchanges 532331:India
Address M Vasanji Road, Ajanta Tower, 54-A, Chakala, Andheri East, Mumbai, MH, IND, 400 093
Ajanta Pharma Ltd is mainly involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages. The operations of the Group are limited to only one segment viz. pharmaceuticals and related products. The company has presence in India, Emerging Market, Africa Institution, and USA. The company generates majority of revenue from Emerging market.
95GF Score

Get the complete analysis for NSE:AJANTPHARM

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3,481.70
Price
₹3,348.50
GF Value